Why Natera, Inc. (NTRA) Stock Rose 21.4% on Aug 7, 2026
The clearest new catalyst: Q2 revenue up 37.7% on record volumes.
Why did NTRA stock rise?
Natera rose 21.37% on Friday, August 7, 2026, closing at $322.10 — a record closing high — after reporting Q2 results the previous evening. Revenue climbed 37.7% year over year to $752.8 million, oncology test volumes grew 57.2% to roughly 296,700, and clinical molecular residual disease units rose 34,000 sequentially, the largest such increase the company has recorded. Natera also lifted full-year 2026 revenue guidance by exactly $100 million at the midpoint, to $2.85–$2.91 billion.
- Q2 revenue up 37.7% on record volumes: Total revenue reached $752.8 million against $546.6 million a year earlier, driven by higher volume and average selling price improvements. Natera processed approximately 1,043,900 tests, up 22.4%, marking a second consecutive quarter above one million.
- Oncology and MRD momentum: Oncology tests grew 57.2% to roughly 296,700, and clinical molecular residual disease units increased 34,000 over the first quarter — the largest sequential gain to date. This is the part of the business that carries the Signatera franchise and the bulk of the growth narrative.
- Full-year guidance raised $100 million at the midpoint: Natera lifted 2026 revenue guidance from $2.74–$2.82 billion to $2.85–$2.91 billion, guided gross margin to approximately 64%–66%, and reiterated an expectation of positive cash flow. Note that positive cash flow is not the same as GAAP profitability.
- Losses narrowed but the company remains loss-making: Loss from operations narrowed to $75.8 million from $110.4 million, and GAAP net loss narrowed to $67.0 million, or $0.47 per diluted share, from $100.9 million and $0.74. Natera is not GAAP profitable and states it expects net losses for the foreseeable future.
How the story developed
- June 11, 2026Shareholders approved the amendment adding 3.2 million shares to Natera's 2015 Equity Incentive Plan — the change later registered on Form S-8.
- August 6, 2026Natera reported Q2 2026 results after the market close, with the conference call at 4:30 p.m. ET. Shares had closed that day at $265.38.
- August 7, 2026Shares rose 21.37% to close at $322.10, a record closing high, after touching $323.01 intraday. A routine Form S-8 registering the already-approved plan shares was filed the same day.
What it could mean for NTRA investors
The constructive case
- Oncology volume growth of 57.2% and a record 34,000-unit sequential increase in clinical MRD units point to genuine share capture in the highest-value part of the portfolio.
- Raising full-year guidance by $100 million at the midpoint one quarter after setting it signals management confidence rather than a one-quarter beat.
- Losses narrowed materially — operating loss fell to $75.8 million from $110.4 million — while the company held roughly $1.09 billion in cash, cash equivalents and restricted cash against $80.3 million of debt.
The cautious case & what could invalidate it
- Natera remains GAAP loss-making and states it expects net losses for the foreseeable future; guidance for positive cash flow is a different measure and should not be read as profitability.
- The headline 64.5% gross margin benefited from a $52.3 million revenue-accrual true-up; on the company's own ex-true-up basis, gross margin improved only about 50 basis points sequentially.
- The move re-rated the shares to a record close, so the main risk is simply failing to sustain the MRD volume and ASP trajectory now embedded in expectations.
- Reimbursement and average-selling-price progress drive much of the growth algorithm — any slippage there would challenge the valuation implied by this session.
Initial detection
BestStocks first flagged NTRA intraday on Aug 7, 2026; this analysis was finalized after the close using the confirmed +21.4% session move and additional catalyst research.
Show the initial intraday note
Natera surged +20.58% to $320.00 following a strong Q2 2026 earnings beat released after market close on August 6. The company reported revenue of $752.8 million, 37.7% YoY growth and well above the ~$661M consensus estimate, while narrowing its GAAP loss to $0.47 per share. Management raised full-year 2026 guidance to $2.85–$2.91B from $2.74–$2.82B, citing record test volumes of 1.04M (56% YoY growth in Signatera MRD units). Volume stands at 2.17M shares, 2.72x the time-adjusted average.
What to watch next: Monitor Natera's stock action at the close and watch for any post-earnings analyst upgrades or price-target revisions; track Signatera adoption trends and quarterly MRD test volume growth in future earnings reports.
Frequently asked questions
Why did Natera, Inc. (NTRA) stock rise on Aug 7, 2026?
Natera rose 21.37% on Friday, August 7, 2026, closing at $322.10 — a record closing high — after reporting Q2 results the previous evening. Revenue climbed 37.7% year over year to $752.8 million, oncology test volumes grew 57.2% to roughly 296,700, and clinical molecular residual disease units rose 34,000 sequentially, the largest such increase the company has recorded. Natera also lifted full-year 2026 revenue guidance by exactly $100 million at the midpoint, to $2.85–$2.91 billion.
How much did NTRA stock rise on Aug 7, 2026?
NTRA rose 21.4% during the Aug 7, 2026 trading session.
What were the main drivers behind NTRA's move?
Q2 revenue up 37.7% on record volumes; Oncology and MRD momentum; Full-year guidance raised $100 million at the midpoint; Losses narrowed but the company remains loss-making.